Baxter

RegulatoryAugust 11, 2026

FDA Approval Application for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride by Lupin

Lupin has submitted an Abbreviated New Drug Application (ANDA 216095) for a combination product containing Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride, currently under standard review by the FDA.

Sponsor company

Recent signals(5)

FDA Approval Application for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride by Lupin

Baxter Faces Early Alert Over Intravascular Administration Set Air Bubble Issue

Baxter Issues Correction for Volera Positive Pressure Breathing Devices Due to Air Leakage

Baxter Healthcare's Dexmedetomidine Hydrochloride ANDA208103 Receives AP Status

Baxter's Volara System Faces Air Leak Issues Impacting Patient Therapy

Upcoming milestones

Related catalysts(2)

— Baxter

— Baxter

Indications

Therapeutic areas

Get signals before the market moves